London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Again Novacyt goes up whilst Yourgene doesn't, even with all buys late yesterday and first thing today. Go figure.
Standard test being sold for $700 dollars.
good summary there flipper, cheers!
For clarity it won't affect NIPT production as below states;
'Should the requirement to produce COVID-19 tests expand, the Company may need to increase capacity to replenish PCR stocks and maintain continuity of supply of existing Yourgene product lines. The Company is well prepared to do this and is able to utilise its expertise in automation to assist in the scale up of production'.
I would suggest that this is more of a reflection of the scale of testing required, and also globally at the same time. It perhaps should be seen as a similar global distribution arrangement that Novacyt signed with Bruker-Hain Diagnostics for its COVID-19 test with. Although some noise was caused by the RP interview last night on the validity of some of these COVID-19 tests it should be noted the pedigree of Primerdesign which developed the H1N1 'swine flu' detection kit. By way of background Primerdesign, is Novacyt's molecular diagnostics division based in the UK. In addition it could be noted that Bruker also has past pedigree with a CE-IVD marked genesig assay kit for the Detection of the SARS-CoV-2. The Primerdesign COVID-19 test has already been approved in India, Argentina and received FDA approval in the Philippines as well so some of the jitters seen today on the Novacyt BB today was overblown. In many ways the Yourgene involvement is due to help with the overspill as they have a similar technological base to Primerdesign, and can supply PCR (polymerase chain reaction). What this is in layman's speak is a technique used to make numerous copies of a specific segment of DNA quickly and accurately. The polymerase chain reaction enables investigators to obtain the large quantities of DNA which they can then use the COVID-19 test on.
At present this supply arrangement is in addition to YGEN's existing sales which according to the CEO have proved quite resilient to the current crisis and which if true should support the current sp on a Enterprise Value to Sales ratio. It could be noted that the original RNS was for a "support the manufacture of critical components for the production of COVID-19 diagnostic tests, whilst continuing its own PCR (polymerase chain reaction) production."
The recent furore of testing would suggest that this more limited involvement will rapidly be expanded "to utilize Yourgene's ability to produce final versions of the COVID-19 testing kits" as also alluded to in the original RNS. This would have a negative impact on the NIPT side of business as it would divert the PCR stocks from NIPT purposes. So I suspect behind the scenes you may be seeing some scaling up of production and expansion of laboratory capabilities to support the NHS in COVID-19 laboratory service testing at the same time as continuing its core NIPT line as a precursor to a further RNS.
The headroom from the latest funding should cover both this scaling up and replenishment of PCR stocks but regardless the volumetrics would pay for itself and you should see a sp appreciation accordingly
Many thanks bakky. I’m new to Yourgene, so not as informed as others here.
Simon. I wouldn't worry at all .There is plenty for everyone. Ygen will be very busy both with NHS testing and work for NCYT. The 'big' pharmas coming in will not take any work away from Ygen, who will be flat out, as they all will be. There is more than enough to go around. I would think your investment here is safer than most at this present time. There are a few good news rns's to come here in the near term, and don't forget the CE approval is imminent too.
The way I see it it looks like the big pharmaceutical firms will be running the testing. Despite them starting from scratch in the UK from what I understand. Novacyt and others will work under them? Where does that leave Yourgene? Can anyone enlighten me? And does my investment still look good in the short and long terms?